Zealand has initiated a clinical trial to evaluate the potential for...
(WorldNews Denmark)

Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide The trial was initiated based upon the positive Phase 2 results reported in June 2017 in patients with short bowel syndrome, which also indicated an extended half-life Copenhagen, Denmark, October 12, 2017 - Zealand Pharma announces dosing has started in a clinical trial with glepaglutide under an investigational new drug application for the treatment of short bowel syndrome . Glepaglutide is a novel long-acting GLP-2 analog under development for the treatment of SBS. ......